BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

255 related articles for article (PubMed ID: 37563605)

  • 21. In vitro assays of the functions of calnexin and calreticulin, lectin chaperones of the endoplasmic reticulum.
    Ireland BS; Niggemann M; Williams DB
    Methods Mol Biol; 2006; 347():331-42. PubMed ID: 17072021
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Cancer Biology of the Endoplasmic Reticulum Lectin Chaperones Calreticulin, Calnexin and PDIA3/ERp57.
    Lam STT; Lim CJ
    Prog Mol Subcell Biol; 2021; 59():181-196. PubMed ID: 34050867
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Involvement of endoplasmic reticulum chaperones in the folding of hepatitis C virus glycoproteins.
    Choukhi A; Ung S; Wychowski C; Dubuisson J
    J Virol; 1998 May; 72(5):3851-8. PubMed ID: 9557669
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Cross-talk between mutant p53 and p62/SQSTM1 augments cancer cell migration by promoting the degradation of cell adhesion proteins.
    Mukherjee S; Maddalena M; Lü Y; Martinez S; Nataraj NB; Noronha A; Sinha S; Teng K; Cohen-Kaplan V; Ziv T; Arandkar S; Hassin O; Chatterjee R; Pirona AC; Shreberk-Shaked M; Gershoni A; Aylon Y; Elazar Z; Yarden Y; Schramek D; Oren M
    Proc Natl Acad Sci U S A; 2022 Apr; 119(17):e2119644119. PubMed ID: 35439056
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Gain-of-function mutant p53 in cancer progression and therapy.
    Zhang C; Liu J; Xu D; Zhang T; Hu W; Feng Z
    J Mol Cell Biol; 2020 Sep; 12(9):674-687. PubMed ID: 32722796
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Therapeutic Ablation of Gain-of-Function Mutant p53 in Colorectal Cancer Inhibits Stat3-Mediated Tumor Growth and Invasion.
    Schulz-Heddergott R; Stark N; Edmunds SJ; Li J; Conradi LC; Bohnenberger H; Ceteci F; Greten FR; Dobbelstein M; Moll UM
    Cancer Cell; 2018 Aug; 34(2):298-314.e7. PubMed ID: 30107178
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Differential downregulation of endoplasmic reticulum-residing chaperones calnexin and calreticulin in human metastatic melanoma.
    Dissemond J; Busch M; Kothen T; Mörs J; Weimann TK; Lindeke A; Goos M; Wagner SN
    Cancer Lett; 2004 Jan; 203(2):225-31. PubMed ID: 14732231
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Mutant p53 drives invasion by promoting integrin recycling.
    Muller PA; Caswell PT; Doyle B; Iwanicki MP; Tan EH; Karim S; Lukashchuk N; Gillespie DA; Ludwig RL; Gosselin P; Cromer A; Brugge JS; Sansom OJ; Norman JC; Vousden KH
    Cell; 2009 Dec; 139(7):1327-41. PubMed ID: 20064378
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Mutant p53 Drives Cancer Metastasis via RCP-Mediated Hsp90α Secretion.
    Zhang S; Wang C; Ma B; Xu M; Xu S; Liu J; Tian Y; Fu Y; Luo Y
    Cell Rep; 2020 Jul; 32(1):107879. PubMed ID: 32640214
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Mutant p53 drives the loss of heterozygosity by the upregulation of Nek2 in breast cancer cells.
    Ghaleb A; Padellan M; Marchenko N
    Breast Cancer Res; 2020 Dec; 22(1):133. PubMed ID: 33267874
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Soluble tyrosinase is an endoplasmic reticulum (ER)-associated degradation substrate retained in the ER by calreticulin and BiP/GRP78 and not calnexin.
    Popescu CI; Paduraru C; Dwek RA; Petrescu SM
    J Biol Chem; 2005 Apr; 280(14):13833-40. PubMed ID: 15677452
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Integrin alpha5 in human breast cancer is a mediator of bone metastasis and a therapeutic target for the treatment of osteolytic lesions.
    Pantano F; Croset M; Driouch K; Bednarz-Knoll N; Iuliani M; Ribelli G; Bonnelye E; Wikman H; Geraci S; Bonin F; Simonetti S; Vincenzi B; Hong SS; Sousa S; Pantel K; Tonini G; Santini D; Clézardin P
    Oncogene; 2021 Feb; 40(7):1284-1299. PubMed ID: 33420367
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Crizotinib Nanomicelles Synergize with Chemotherapy through Inducing Proteasomal Degradation of Mutp53 Proteins.
    Yi T; Qian J; Ye Y; Zhang H; Jin X; Wang M; Yang Z; Zhang W; Wen L; Zhang Y
    ACS Appl Mater Interfaces; 2023 Jan; 15(1):511-523. PubMed ID: 36578131
    [TBL] [Abstract][Full Text] [Related]  

  • 34. DNAJA1 promotes cancer metastasis through interaction with mutant p53.
    Kaida A; Yamamoto S; Parrales A; Young ED; Ranjan A; Alalem MA; Morita KI; Oikawa Y; Harada H; Ikeda T; Thomas SM; Diaz FJ; Iwakuma T
    Oncogene; 2021 Aug; 40(31):5013-5025. PubMed ID: 34183772
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Autophagy induced by SAHA affects mutant P53 degradation and cancer cell survival.
    Foggetti G; Ottaggio L; Russo D; Mazzitelli C; Monti P; Degan P; Miele M; Fronza G; Menichini P
    Biosci Rep; 2019 Feb; 39(2):. PubMed ID: 30745455
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Beyond lectins: the calnexin/calreticulin chaperone system of the endoplasmic reticulum.
    Williams DB
    J Cell Sci; 2006 Feb; 119(Pt 4):615-23. PubMed ID: 16467570
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Upregulation of microRNA-31 targeting integrin α5 suppresses tumor cell invasion and metastasis by indirectly regulating PI3K/AKT pathway in human gastric cancer SGC7901 cells.
    Zhang XB; Song L; Wen HJ; Bai XX; Li ZJ; Ma LJ
    Tumour Biol; 2016 Jun; 37(6):8317-25. PubMed ID: 26729197
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The interplay between mutant p53 and the mevalonate pathway.
    Parrales A; Thoenen E; Iwakuma T
    Cell Death Differ; 2018 Mar; 25(3):460-470. PubMed ID: 29238070
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Glutathionylation-dependent proteasomal degradation of wide-spectrum mutant p53 proteins by engineered zeolitic imidazolate framework-8.
    Zhang Y; Huang X; Wang L; Cao C; Zhang H; Wei P; Ding H; Song Y; Chen Z; Qian J; Zhong S; Liu Z; Wang M; Zhang W; Jiang W; Zeng J; Yao G; Wen LP
    Biomaterials; 2021 Apr; 271():120720. PubMed ID: 33639563
    [TBL] [Abstract][Full Text] [Related]  

  • 40. TRRAP is essential for regulating the accumulation of mutant and wild-type p53 in lymphoma.
    Jethwa A; Słabicki M; Hüllein J; Jentzsch M; Dalal V; Rabe S; Wagner L; Walther T; Klapper W; ; Bohnenberger H; Rettel M; Lu J; Smits AH; Stein F; Savitski MM; Huber W; Aylon Y; Oren M; Zenz T
    Blood; 2018 Jun; 131(25):2789-2802. PubMed ID: 29653964
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.